CN115003675A - 作为5-羟色胺受体7调节剂的新型官能化内酰胺及其使用方法 - Google Patents

作为5-羟色胺受体7调节剂的新型官能化内酰胺及其使用方法 Download PDF

Info

Publication number
CN115003675A
CN115003675A CN202080093159.6A CN202080093159A CN115003675A CN 115003675 A CN115003675 A CN 115003675A CN 202080093159 A CN202080093159 A CN 202080093159A CN 115003675 A CN115003675 A CN 115003675A
Authority
CN
China
Prior art keywords
alkyl
group
unsubstituted
cycloalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080093159.6A
Other languages
English (en)
Chinese (zh)
Inventor
D·J·坎尼
B·E·布拉斯
K·M·布拉特纳
D·A·皮平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plewetix Co ltd
Tempel University Commonwealth Higher Education System
Original Assignee
Plewetix Co ltd
Tempel University Commonwealth Higher Education System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plewetix Co ltd, Tempel University Commonwealth Higher Education System filed Critical Plewetix Co ltd
Publication of CN115003675A publication Critical patent/CN115003675A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202080093159.6A 2019-11-13 2020-11-12 作为5-羟色胺受体7调节剂的新型官能化内酰胺及其使用方法 Pending CN115003675A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934997P 2019-11-13 2019-11-13
US62/934,997 2019-11-13
PCT/US2020/060270 WO2021097116A1 (en) 2019-11-13 2020-11-12 Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use

Publications (1)

Publication Number Publication Date
CN115003675A true CN115003675A (zh) 2022-09-02

Family

ID=74068668

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080093159.6A Pending CN115003675A (zh) 2019-11-13 2020-11-12 作为5-羟色胺受体7调节剂的新型官能化内酰胺及其使用方法

Country Status (12)

Country Link
US (1) US20230002383A1 (https=)
EP (1) EP4058455A1 (https=)
JP (2) JP7730811B2 (https=)
KR (1) KR20220113702A (https=)
CN (1) CN115003675A (https=)
AU (1) AU2020381460A1 (https=)
BR (1) BR112022009374A2 (https=)
CA (1) CA3160801A1 (https=)
IL (1) IL292811A (https=)
MX (1) MX2022005820A (https=)
TW (1) TWI905129B (https=)
WO (1) WO2021097116A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49019A (fr) 2017-03-21 2020-02-05 Univ Temple Nouveaux modulateurs du récepteur sigma 2 et leur procédé d'utilisation
EA202092328A1 (ru) 2018-05-11 2021-04-08 Темпл Юниверсити-Оф Зэ Коммонвелс Систем Оф Хаер Эдьюкейшн Новые функционализированные лактамы в качестве модуляторов 5-гидрокситриптаминового рецептора 7 и способ их применения

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130053372A1 (en) * 2010-02-15 2013-02-28 Cambridge Enterprise Limited 5-ht receptor modulators
WO2014164756A1 (en) * 2013-03-11 2014-10-09 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2016040554A1 (en) * 2014-09-10 2016-03-17 Temple University-Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2018093818A1 (en) * 2016-11-15 2018-05-24 Temple University-Of The Commonwealth System Of Higher Education Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use
WO2019094856A1 (en) * 2017-11-13 2019-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Atypical inhibitors of monoamine transporters; method of making; and use thereof
WO2019217890A1 (en) * 2018-05-11 2019-11-14 Temple University-Of The Commonwealth System Of Higher Education Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7365238B2 (ja) 2017-03-21 2023-10-19 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション ５－ヒドロキシトリプタミン受容体７調節物質および治療剤としてのその使用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130053372A1 (en) * 2010-02-15 2013-02-28 Cambridge Enterprise Limited 5-ht receptor modulators
WO2014164756A1 (en) * 2013-03-11 2014-10-09 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2016040554A1 (en) * 2014-09-10 2016-03-17 Temple University-Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US20170298037A1 (en) * 2014-09-10 2017-10-19 Temple University-Of The Commonwealth System Of Higher Education Novel 5-Hydroxytryptamine Receptor 7 Activity Modulators and Their Method of Use
WO2018093818A1 (en) * 2016-11-15 2018-05-24 Temple University-Of The Commonwealth System Of Higher Education Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use
WO2019094856A1 (en) * 2017-11-13 2019-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Atypical inhibitors of monoamine transporters; method of making; and use thereof
US20210024523A1 (en) * 2017-11-13 2021-01-28 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Atypical inhibitors of monoamine transporters; method of making; and use thereof
WO2019217890A1 (en) * 2018-05-11 2019-11-14 Temple University-Of The Commonwealth System Of Higher Education Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use
CN112437768A (zh) * 2018-05-11 2021-03-02 英联邦高等教育系统坦普尔大学 作为5-羟色胺受体7调节剂的新型官能化内酰胺及其使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERIK DÍAZ-CERVANTES ET AL.: "In vitro and in silico evaluation of twelve newly-synthesized 1-acetamide-5-methoxy-2-oxindoles as 5-Ht7 receptor ligands", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, vol. 25, pages 1580 - 1585, XP029148565, DOI: 10.1016/j.bmcl.2015.02.008 *
汪涛等: "基于5-羟色胺转运蛋白和sigma-1受体的苯基哌嗪烷胺类化合物的设计、合成及抗抑郁活性研究", 《中国药物化学杂志》, vol. 27, pages 423 - 433 *

Also Published As

Publication number Publication date
WO2021097116A1 (en) 2021-05-20
CA3160801A1 (en) 2021-05-20
TWI905129B (zh) 2025-11-21
AU2020381460A1 (en) 2022-06-09
JP7730811B2 (ja) 2025-08-28
IL292811A (en) 2022-07-01
US20230002383A1 (en) 2023-01-05
JP2023501577A (ja) 2023-01-18
MX2022005820A (es) 2022-08-16
EP4058455A1 (en) 2022-09-21
JP2025161894A (ja) 2025-10-24
BR112022009374A2 (pt) 2022-08-09
KR20220113702A (ko) 2022-08-16
TW202132301A (zh) 2021-09-01

Similar Documents

Publication Publication Date Title
JP7461104B2 (ja) Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2026048784A (ja) Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体
TWI856012B (zh) 作為5-羥基色胺受體7之調節劑之新穎官能化內醯胺及其使用方法
KR102590403B1 (ko) 5-히드록시트립타민 수용체 7의 신규 조절제 및 이의 사용 방법
CN114945575B (zh) 作为5-羟色胺受体7调节剂的新型官能化内酯及其使用方法
WO2019205983A1 (zh) 氧杂螺环类化合物及其制备方法和用途
JP2025161894A (ja) ５－ヒドロキシトリプタミン受容体７の調節因子としての新規官能化ラクタムおよびその使用方法
US10584116B2 (en) Heterocyclic sulfonamide derivative and medicine containing same
TW202333663A (zh) Rxfp1促效劑
JP6045083B2 (ja) ジアゾナミドアナログ
HK40119675A (zh) 作为5-羟色胺受体7调节剂的新型官能化内酯及其使用方法
KR20260053219A (ko) 5-히드록시트립타민 수용체 7의 신규 조절제 및 이의 사용 방법
HK40014762A (en) 3-(2-(4-phenylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one derivatives and related compounds as 5-hydroxytryptamine receptor 7 (5-ht7) modulators for treating e.g. inflammatory bowel disease, circadian rhythm disorder or depression
HK40014762B (en) 3-(2-(4-phenylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one derivatives and related compounds as 5-hydroxytryptamine receptor 7 (5-ht7) modulators for treating e.g. inflammatory bowel disease, circadian rhythm disorder or depression

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination